441 related articles for article (PubMed ID: 22993227)
1. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
Espígol-Frigolé G; Corbera-Bellalta M; Planas-Rigol E; Lozano E; Segarra M; García-Martínez A; Prieto-González S; Hernández-Rodríguez J; Grau JM; Rahman MU; Cid MC
Ann Rheum Dis; 2013 Sep; 72(9):1481-7. PubMed ID: 22993227
[TBL] [Abstract][Full Text] [Related]
2. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Queralt C; Grau JM; Urbano-Márquez A; Palacín A; Colomer D; Cid MC
Rheumatology (Oxford); 2004 Mar; 43(3):294-301. PubMed ID: 14679293
[TBL] [Abstract][Full Text] [Related]
3. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
[TBL] [Abstract][Full Text] [Related]
4. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis.
Ciccia F; Rizzo A; Guggino G; Cavazza A; Alessandro R; Maugeri R; Cannizzaro A; Boiardi L; Iacopino DG; Salvarani C; Triolo G
Rheumatology (Oxford); 2015 Sep; 54(9):1596-604. PubMed ID: 25862016
[TBL] [Abstract][Full Text] [Related]
5. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis.
Cid MC; Hoffman MP; Hernández-Rodríguez J; Segarra M; Elkin M; Sánchez M; Vilardell C; García-Martínez A; Pla-Campo M; Grau JM; Kleinman HK
Rheumatology (Oxford); 2006 Nov; 45(11):1356-63. PubMed ID: 16621921
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.
Terrier B; Geri G; Chaara W; Allenbach Y; Rosenzwajg M; Costedoat-Chalumeau N; Fouret P; Musset L; Benveniste O; Six A; Klatzmann D; Saadoun D; Cacoub P
Arthritis Rheum; 2012 Jun; 64(6):2001-11. PubMed ID: 22147555
[TBL] [Abstract][Full Text] [Related]
7. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
8. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.
Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Grau JM; Urbano-Márquez A; Colomer D; Kleinman HK; Cid MC
Circulation; 2003 May; 107(19):2428-34. PubMed ID: 12742994
[TBL] [Abstract][Full Text] [Related]
9. Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.
Espígol-Frigolé G; Planas-Rigol E; Lozano E; Corbera-Bellalta M; Terrades-García N; Prieto-González S; García-Martínez A; Hernández-Rodríguez J; Grau JM; Cid MC
Front Immunol; 2018; 9():809. PubMed ID: 29731755
[TBL] [Abstract][Full Text] [Related]
10. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis.
Ciccia F; Alessandro R; Rizzo A; Raimondo S; Giardina A; Raiata F; Boiardi L; Cavazza A; Guggino G; De Leo G; Salvarani C; Triolo G
Ann Rheum Dis; 2013 Feb; 72(2):258-64. PubMed ID: 22872024
[TBL] [Abstract][Full Text] [Related]
11. Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.
Corbera-Bellalta M; García-Martínez A; Lozano E; Planas-Rigol E; Tavera-Bahillo I; Alba MA; Prieto-González S; Butjosa M; Espígol-Frigolé G; Hernández-Rodríguez J; Fernández PL; Roux-Lombard P; Dayer JM; Rahman MU; Cid MC
Ann Rheum Dis; 2014 Mar; 73(3):616-23. PubMed ID: 23625984
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events.
Lozano E; Segarra M; Corbera-Bellalta M; García-Martínez A; Espígol-Frigolé G; Plà-Campo A; Hernández-Rodríguez J; Cid MC
Ann Rheum Dis; 2010 Feb; 69(2):434-42. PubMed ID: 19289383
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma.
Furuzawa-Carballeda J; Ortíz-Ávalos M; Lima G; Jurado-Santa Cruz F; Llorente L
Clin Exp Dermatol; 2012 Aug; 37(6):599-609. PubMed ID: 22731679
[TBL] [Abstract][Full Text] [Related]
14. Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et al.
Samson M; Audia S; Janikashvili N; Bonnotte B
Ann Rheum Dis; 2013 May; 72(5):e3. PubMed ID: 23475980
[No Abstract] [Full Text] [Related]
15. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis.
Coit P; De Lott LB; Nan B; Elner VM; Sawalha AH
Ann Rheum Dis; 2016 Jun; 75(6):1196-202. PubMed ID: 26038090
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.
García-Martínez A; Hernández-Rodríguez J; Espígol-Frigolé G; Prieto-González S; Butjosa M; Segarra M; Lozano E; Cid MC
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):835-41. PubMed ID: 20535794
[TBL] [Abstract][Full Text] [Related]
17. Temporal artery biopsy is not required in all cases of suspected giant cell arteritis.
Quinn EM; Kearney DE; Kelly J; Keohane C; Redmond HP
Ann Vasc Surg; 2012 Jul; 26(5):649-54. PubMed ID: 22285348
[TBL] [Abstract][Full Text] [Related]
18. Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling.
Ly KH; Régent A; Molina E; Saada S; Sindou P; Le-Jeunne C; Brézin A; Witko-Sarsat V; Labrousse F; Robert PY; Bertin P; Bourges JL; Fauchais AL; Vidal E; Mouthon L; Jauberteau MO
Arthritis Res Ther; 2014 Nov; 16(6):487. PubMed ID: 25418464
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of visual outcome after visual loss from giant cell arteritis.
Danesh-Meyer H; Savino PJ; Gamble GG
Ophthalmology; 2005 Jun; 112(6):1098-103. PubMed ID: 15885780
[TBL] [Abstract][Full Text] [Related]
20. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
